Anastrozole: A selective aromatase inhibitor for the treatment of breast cancer

American Journal of Health-System Pharmacy

Volumn 55, Issue 5, 1998, Pages 445-452

  Higa, Gerald M ^a,b   Alkhouri, Nabiel ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Anastrozole; Antineoplastic agents; Breast neoplasms; Cost; Dosage; Pharmacokinetics; Toxicity

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; CHOLESTEROL; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR; ESTROGEN; ESTROGEN RECEPTOR; FADROZOLE; FLUOXYMESTERONE; FORMESTANE; GESTAGEN; GONADORELIN AGONIST; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; PREGNENOLONE; PROGESTERONE RECEPTOR; SOMATOMEDIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ADRENALECTOMY; ASTHENIA; BACKACHE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL THERAPY; HUMAN; HYPOPHYSECTOMY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0032032395     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.5.445     Document Type: Review

References (91)

1. Parkin DM, Muir CS, Whelan SI et al. Cancer Incidence In five continents. Vol VI. Lyon, France: IARC Scientific Publication; 1992.
2. Langsten AA, Malone KE, Thompson JD et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996; 334:137-42.
3. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian Incidence. Am J Hum Genet. 1995; 57:1457-62.
4. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer. 1993; 55:891-903.
5. Simes RJ, Cocker K, Glasziou P et al. Costs and benefits of adjuvant chemotherapy for breast cancer: an assessment of patient preference. Proc Am Soc Clin Oncol 1989; 8:52.
6. Bonadonna G, Valagusa P. Adjuvant chemoendocrine therapy in breast cancer. J Clin Oncol 1986; 4:451-4.
7. Click JH, Creech RH, Torri S et al. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. Cancer. 1980; 45:735-41.
8. Bezwoda WR, Derman D, DeMoor NG et al. Treatment of metastatic breast cancer in estrogen receptor positive patients: a randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. Cancer. 1982; 50:2747-50.
9. Cavalli F, Beer M, Martz G et al. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J. 1983; 286:5-8.
10. Australian and New Zealand Breast Cancer Trials Group. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol. 1986; 4:186-93.
11. Fisher B, Brown A, Wolmark N et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987; 106:649-54.
12. Castiglione M, Belber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol. 1990; 8:519-26.
13. Taylor SG, Gelman RS, Falkson G et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986; 104:455-61.
14. Nayfield SG, Karp JE, Ford LG et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83:1450-9.
15. Lippman M, Dickson R. Growth regulation of normal and malignant breast epithelium. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant diseases. Philadelphia: Saunders; 1991:363-94.
16. Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 1987; 47:707-12.
17. Knabbe C, Lippman ME, Wakefield LM et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987; 48:417-28.
18. Hirayama T, Wynder EL. Study of epidemiology of cancer of the breast: influence of hysterectomy. Cancer. 1962; 15:28-38.
19. MacMahon B, Feinlieb M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst. 1960; 24:733-53.
20. Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet. 1995; 346:883-7.
21. Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatlc breast cancer. Clin Oncol. 1986; 4:178-85.
22. Ewertz M. Influence of noncontraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 1988; 42:832-8.
23. Brinton LA, Hoover RN, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986; 54:825-32.
24. Hoover R, Glass A, Findle WD et al. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981; 67:815- 20.
25. Brinton LA, Hoover RN, Szlo M et al. Menopausal estrogen use and risk of breast cancer. Cancer. 1981; 47:2517-22.
26. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896; 2:104-7, 162-5.
27. Henderson IC, Canellos GP. Cancer of the breast. N Engl J Med. 1980; 302:1730.
28. Ross RK, Paganini-Hill A, Gerkins VR et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980; 243:1635-9.
29. Ratzkowski E, Adler B, Hochman A, Survival time and treatment results of patients with disseminated breast cancer especially after adrenalectomy and hypophysectomy. Oncology. 1973; 28:385-97.
30. Cole MP, Jones CTA, Todd IDH. A new antioestrogenic agent in late breast cancer. An early clinical appraisal with ICI 46474. Br J Cancer. 1971; 25:270-5.
31. Conn PM, Browley WF. Gonadotropin-releaslng hormone and its analogues. N Engl J Med. 1991; 324:93-103.
32. Thompson EA, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human pla cental mlcrosomes during aromatization of androstenedione. J Biol Chem. 1974; 249:5364-72.
33. Lundgren S, Lonning PE, Utaaker E et al. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer. 1. General findings. J Steroid Biochem. 1990; 36:99-104.
34. Blossey HC, Wander HE, Koebberllng J et al. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer. 1984; 54:1208-15.
35. Henderson IC, Harris JR, Kinne DW et al. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. Philadelphia: Lippincott; 1993:1264-324.
36. Jensen EV, Block GE, Smith S et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 1971 (Dec); 34:55-70.
37. Edwards DP, Chamness GC, McGuire WL. Estrogen and progesterone receptor proteins in breast cancer. Biochem Biophys Acta. 1979; 560:457-86.
38. Clark GM, McGuire WL. Progesterone receptors and human breast cancer. Breast Cancer Res Treat, 1983; 3:157-63.
39. Imai Y, Leung CKH, Friesen HG et al. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long term culture. Cancer Res. 1982; 42:4394-8.
40. Reddel RR, Murphy LC, Hall RE et al. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res. 1985; 45:1525-31.
41. Patterson JS. Nolvadex (tamoxifen) as an anticancer agent in humans. In: Sutherland RL, Jordan VC, eds. Non-steroidal antloestrogens. Sydney, Australia: Academic; 1981:143-63.
42. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med. 1988; 109:219-28.
43. Manni A, Trujillo JE, Marshall JS et al. Anti-hormone treatment of stage IV breast cancer. Cancer. 1979; 43:444-50.
44. Ward HWC, Arthur K, Banks AJ et al. Anti-oestrogen therapy for breast cancer - a report on 300 patients treated with tamoxifen. Clin Oncol. 1978; 4:11-7.
45. Henderson IC. Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson 1C et al., eds. Breast diseases. Philadelphia: Lippincott; 1987:398-428.
46. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Cancer Res. 1990; 50:4177-89.
47. Buchanan RB, Blarney RW, Durrant KR et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986; 4:1326-30.
48. Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 1986; 4:178-85.
49. Manni A, Pearson OH. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980; 64:779-84.
50. Kimmick G, Muss HB. Current status of endocrine therapy for metastatic breast cancer. Oncology. 1995; 9:877-90.
51. Sawka CA, Pritchard KI, Paterson AHG et al. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res. 1986; 46:3152-6.
52. Harris AL, Dowsett M, Jeffcoate SL et al. Endocrine and therapeutic effects of amlnoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab. 1982; 55:718-20.
53. Lippman ME. The NIH concensus development conference on adjuvant chemotherapy for breast cancer - a commentary. Breast Cancer Res Treat, 1985; 6:195-200.
54. Falkson G, Holcroft C, Geman RS et al. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1453-8.
55. Osborne CK. Receptors. In: Harris JR, Hellman S, Henderson IC et al., eds. Breast diseases. Philadelphia: Lippincott; 1987:210-32.
56. Pearson OH, Manni A, Arafah BM. Antiestrogen treatment of breast cancer: an overview. Cancer Res. 1982; 42(suppl):3424- 9.
57. Ettinger DS, Allegra J, Bertino JR et al. Megestrol acetate versus tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol. 1986; 13(suppl 4):L9-14.
58. Morgan LR. Megestrol acetate versus tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1986; 12(suppl 1):43-7.
59. Smith IE, Harris AL, Morgan M et al. Tamoxifen versus amlnoglutethimlde in advanced breast carcinoma: a randomized cross-over trial. Br Med J . 1981; 283:1432-4.
60. Ingle JN, Ahmann DL, Green SJ et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981; 304:16-21.
61. Westerberg H. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep. 1980; 64:117-21.
62. Mouridsen HT, Ellemann K, Mattsson W et al. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep. 1979; 63:171-5.
63. Tormey DC, Lippman ME, Edwards BK et al. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med. 1983; 98:139-44.
64. Milsted R, Habeshaw T, Kaye S et al. A randomized trial of tamoxifen versus tamoxifen with aminoglutethlmide in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 1985; 14:272-3.
65. Stewart JF, Rubens RD, King RJB et al. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1982; 18:1307-14.
66. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973; 36:207-14.
67. Nemoto T, Patel J, Rosner D et al. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer. 1984; 53:1333-5.
68. Moore FD, VanDevanter SB, Boyden CM et al. Adrenalectomy with chemotherapy in the treatment of advanced breast cancer: objective and subjective response rates; duration and quality of life. Surgery. 1974; 76:376-88.
69. Klang DT, Frenning DH, Vosika GJ et al. Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer. 1980; 45:1322-5.
70. Dowsett M. Inhibitors of steroidogenic enzymes for the treatment of breast cancer. J Steroid Biochem Mol Biol, 1991; 39:805- 9.
71. Brueggemeier RW. Biochemical and molecular aspects of aromatase. J Enzym Inhib. 1990; 4:101-11.
72. Brodie AMH. Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Mol Biol 1994; 49:281-7.
73. O'Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant disease. Br J Cancer. 1987; 56:601-4.
74. Griffiths CT, Hall TC, Saba Z et al. Preliminary trial of aminoglutethimide in breast cancer. Cancer. 1973; 32:31-47.
75. Lipton A, Santen RJ. Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer. 1974; 33:503-12.
76. Newsome HH, Brown PN, Terz JJ et al. Medical and surgical adrenalectomy In patients with advanced breast carcinoma. Cancer. 1977; 39:542-6.
77. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4- hydroxyandrostenedione: phase II report. Cancer Res. 1986; 46:4823-6.
78. Santen RJ, Demers LM, Adlercreutz H et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab. 1989; 68:99-106.
79. Schieweck K, Bhatnagar AS, Batzl CH et al. Antitumor and endocrine effects of nonsteroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993; 44:633-6.
80. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post- menopausal women with breast cancer. Br J Cancer. 1996; 74:1286-91.
81. Vanden BH, Moereels H, Koymans LMH. Aromatase inhibitors - mechanisms for non-steroidal inhibitors. Breast Cancer Res Treat. 1994; 30:43-55.
82. Plourde PV, Yates RA, Dyroff M et al. The effect of Arimidex, a new potent aromatase inhibitor, on circulating estrogens in post-menopausal women. Proc Am Soc Clin Oncol. 1993; 12:A165.
83. Wolter J, Robert N, Harvey H et al. Arimidex (ZD 1033): a phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 1995; 14:A175.
84. Arimidex professional information brochure. Wilmington, DE: Zeneca Pharmaceuticals; 1995 Dec.
85. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994; 30:103-11.
86. Jonat W, Howell A, Blomqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996; 32A:404-12.
87. Buzdar AV, Jones SE, Plourde P et al. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer. 1996; 79:730-9.
88. Buzdar A, Jonat W, Howell A et al. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc Am Soc Clin Oncol. 1997; 16:A156.
89. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase II trials. J Clin Oncol. 1996; 14:2000-11.
90. Simpson ER, Mehendroo MS, Means GD. Tissue-specific promoters regulate cytochrome P-450 expression. J Steroid Biochem Mol Biol. 1993; 44:321-30.
91. Red Book update. 1997; 16(8):20.